Skip to main content

Advertisement

Log in

Medical Treatment of Uterine Leiomyoma

  • Review
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Uterine leiomyomas (also called myomata or fibroids) are the most common gynecologic tumors in the United States. The prevalence of leiomyomas is at least 3 to 4 times higher among African American women than in white women. Pathologically, uterine leiomyomas are benign tumors that arise in any part of the uterus under the influence of local growth factors and sex hormones, such as estrogen and progesterone. These common tumors cause significant morbidity for women and they are considered to be the most common indication for hysterectomy in the world; they are also associated with a substantial economic impact on health care systems that amounts to approximately $2.2 billion/year in the United States alone. Uterine myomas cause several reproductive problems such as heavy or abnormal uterine bleeding, pelvic pressure, infertility, and several obstetrical complications including miscarriage and preterm labor. Surgery has traditionally been the gold standard for the treatment of uterine leiomyomas and has typically consisted of either hysterectomy or myomectomy. In recent years, a few clinical trials have evaluated the efficacy of orally administered medications for the management of leiomyoma-related symptoms. In the present review, we will discuss these promising medical treatments in further detail.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293–298.

    Article  CAS  PubMed  Google Scholar 

  2. Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):655–676.

    Article  PubMed  Google Scholar 

  3. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4):725–736.

    Article  PubMed  Google Scholar 

  4. Drinville Jamie S MS.Benign Disorders of the Uterine Corpus” (Chapter). In: DeCherney AH NL, ed. Curr Diag Treat Obstet Gynecol. 10e, 2010.

  5. Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod. 2010;25(2):418–429.

    Article  PubMed  Google Scholar 

  6. Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 2006;195(4):955–964.

    Article  PubMed  Google Scholar 

  7. Weiss G, Noorhasan D, Schott LL, Powell L, Randolph JF Jr, Johnston JM. Racial differences in women who have a hysterectomy for benign conditions. Womens Health Issues. 2009;19(3):202–210.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Balloch EA. The relative frequency of fibroid processes in the dark skinned races. Med News. 1894;16(2):6.

  9. Roth TM, Gustilo-Ashby T, Barber MD, Myers ER. Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. Obstet Gynecol. 2003;101(5 pt 1):881–884.

    PubMed  Google Scholar 

  10. Othman EE, Al-Hendy A. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):589–601.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Witherspoon JT BV. The etiology of uterine fibroids, with special reference to the frequency of their occurrence in the Negro: an hypothesis. Surg Gynecol Obstet. 1934;58:4.

  12. Torpin R PE, Peeples BS. The etiologic and pathologic factors in a series of 1741 fibromyomas of the uterus. Am J Obstet Gynecol. 1942;44:5.

    Article  Google Scholar 

  13. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988–1990. Obstet Gynecol. 1994;83(4):549–555.

    Article  CAS  PubMed  Google Scholar 

  14. Amant F, Huys E, Geurts-Moespot A, et al. Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. J Soc Gynecol Investig. 2003;10(2):105–109.

    Article  CAS  PubMed  Google Scholar 

  15. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287(16):2106–2113.

    Article  PubMed  Google Scholar 

  16. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003; 188(1):100–107.

    Article  Google Scholar 

  17. Myers ER BM, Couchman GM, Datta S, et al. Management of uterine fibroids (Evidence Report/Technology Assessment No. 34, contract 290-97-0014 to the Duke Evidence-based Practice Center). In: Matchar DB, ed. AHRQ Evidence Reports. Rockville, MD 20852: Agency for Health care research and Quality; 2001.

  18. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70(3):432–439.

    Article  CAS  PubMed  Google Scholar 

  19. Al-Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is associated withincreased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006;13(2):136–144.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang Y, Peng W, Clarke J, Liu Z. Acupuncture for uterine fibroids. Cochrane Database Syst Rev. 2010(1):CD007221.

  21. Viswanathan M, Hartmann K, McKoy N, et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep). 2007;(154):1–122.

  22. Elizabeth A, Stewart M. Overview of treatment of uterine leiomyomas (fibroids). In: Robert L, Barbieri M, ed. Uptodate Online 18.2, 2010.

  23. Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod. 1995;10(7):1795–1796.

    Article  CAS  PubMed  Google Scholar 

  24. Hanafi M. Predictors of leiomyoma recurrence after myomectomy. Obstet Gynecol. 2005;105(4):877–881.

    Article  PubMed  Google Scholar 

  25. Stewart EA, Faur AV, Wise LA, Reilly RJ, Harlow BL. Predictors of subsequent surgery for uterine leiomyomata after abdominal myomectomy. Obstet Gynecol. 2002;99(3):426–432.

    PubMed  Google Scholar 

  26. Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol. 1991;77(4):591–594.

    CAS  PubMed  Google Scholar 

  27. Arena S, Zupi E. Heavy menstrual bleeding: considering the most effective treatment option. Womens Health (Lond Engl). 2011;7(2):143–146.

    Article  Google Scholar 

  28. Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: a possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. Am J Obstet Gynecol. 2004;190(3):639–643.

    Article  PubMed  Google Scholar 

  29. Visvanathan D, Connell R, Hall-Craggs MA, Cutner AS, Bown SG. Interstitial laser photocoagulation for uterine myomas. Am J Obstet Gynecol. 2002;187(2):382–384.

    Article  PubMed  Google Scholar 

  30. Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89(5 pt 2):857.

    Article  CAS  Google Scholar 

  31. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat uterine myomata. Lancet. 1995;346(8976):671–672.

    Article  CAS  PubMed  Google Scholar 

  32. Goodwin SC, Spies JB. Uterine fibroid embolization. N Engl J Med. 2009;361(7):690–697.

    Article  CAS  PubMed  Google Scholar 

  33. Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2006;(1):CD005073.

  34. Freed MM, Spies JB. Uterine artery embolization for fibroids: a review of current outcomes. Semin Reprod Med. 2010;28(3): 235–241.

    Article  PubMed  Google Scholar 

  35. Berkane N, Moutafoff-Borie C. Impact of previous uterine artery embolization on fertility. Curr Opin Obstet Gynecol. 2010;22(3): 242–247.

    Article  PubMed  Google Scholar 

  36. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112(2 pt 1):387–400.

  37. Tse G, Spies JB. Radiation exposure and uterine artery embolization: current risks and risk reduction. Tech Vasc Interv Radiol. 2010;13(3):148–153.

    Article  PubMed  Google Scholar 

  38. Levy BS. Modern management of uterine fibroids. Acta Obstet Gynecol Scand. 2008;87(8):812–823.

    Article  PubMed  Google Scholar 

  39. Stewart EA, Gedroyc WM, Tempany CM, et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol. 2003;189(1):48–54.

    Article  PubMed  Google Scholar 

  40. Hindley J, Gedroyc WM, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol. 2004;183(6):1713–1719.

    Article  PubMed  Google Scholar 

  41. Hesley GK, Felmlee JP, Gebhart JB, et al. Noninvasive treatment of uterine fibroids: early Mayo Clinic experience with magnetic resonance imaging-guided focused ultrasound. Mayo Clin Proc. 2006;81(7):936–942.

    Article  PubMed  Google Scholar 

  42. Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol 2006;108(1):49–54.

    Article  CAS  Google Scholar 

  43. Palomba S, Orio F Jr, Falbo A, Oppedisano R, Tolino A, Zullo F. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. Fertil Steril. 2008;90(1):165–173.

    Article  CAS  PubMed  Google Scholar 

  44. De Leo V, Morgante G, La Marca A, et al. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf. 2002;25(11):759–779.

    Article  PubMed  Google Scholar 

  45. Schally AV, Bowers CY. Purification of Luteinizing Hormone-Releasing Factor from Bovine Hypothalamus. Endocrinology. 1964;75:608–614.

    Article  CAS  PubMed  Google Scholar 

  46. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53–88.

    CAS  PubMed  Google Scholar 

  47. Knobil E. The neuroendocrine control of ovulation. Hum Reprod. 1988;3(4):469–472.

    Article  CAS  PubMed  Google Scholar 

  48. Jeffcoate SL, Greenwood RH, Holland DT. Blood and urine clearance of luteinizing hormone releasing hormone in man measured by radioimmunoassay. J Endocrinol. 1974;60(2):305–314.

    Article  CAS  PubMed  Google Scholar 

  49. Moghissi KS. A clinician’s guide to the use of gonadotropin-releasing hormone analogues in women. Medscape General Medicine, 2000. http://www.medscape.com/viewarticle/408909.

  50. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485–504.

    Article  CAS  PubMed  Google Scholar 

  51. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391–405.

    Article  CAS  PubMed  Google Scholar 

  52. Donnez J, Hervais Vivancos B, Kudela M, Audebert A, Jadoul P. A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil Steril. 2003;79(6):1380–1389.

    Article  PubMed  Google Scholar 

  53. Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril. 1997;67(5):837–841.

    Article  CAS  PubMed  Google Scholar 

  54. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991;77(5):720–725.

    CAS  PubMed  Google Scholar 

  55. Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25(3):642–653.

    Article  CAS  PubMed  Google Scholar 

  56. Palomba S, Russo T, Orio F Jr, et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002;17(12):3213–3219.

    Article  CAS  PubMed  Google Scholar 

  57. Chen W, Yoshida S, Ohara N, Matsuo H, Morizane M, Maruo T. Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(Adenosine 5′-Diphosphate-Ribose) polymerase expression in cultured human leiomyoma cells. J Clin Endocrinol Metab. 2005;90(2):884–892.

    Article  CAS  PubMed  Google Scholar 

  58. Wiznitzer A, Marbach M, Hazum E, Insler V, Sharoni Y, Levy J. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun. 1988;152(3):1326–1331.

    Article  CAS  PubMed  Google Scholar 

  59. Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med. 2010;362(8):752–754.

    Article  CAS  PubMed  Google Scholar 

  60. Wang PH, Lee WL, Cheng MH, Yen MS, Chao KC, Chao HT. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas. Taiwan J Obstet Gynecol. 2009;48(2):133–137.

    Article  PubMed  Google Scholar 

  61. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22(4):283–288.

    PubMed  Google Scholar 

  62. Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):307–331.

    Article  PubMed  Google Scholar 

  63. Matsuo H. Bone loss induced by GnRHa treatment in women [in Japanese]. Nippon Rinsho. 2003;61(2):314–318.

    PubMed  Google Scholar 

  64. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111(6):585–593.

    Article  CAS  PubMed  Google Scholar 

  65. West CP, Lumsden MA, Hillier H, Sweeting V, Baird DT. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod. 1992;7(3):328–332.

    Article  CAS  PubMed  Google Scholar 

  66. Caird LE, West CP, Lumsden MA, Hannan WJ, Gow SM. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Hum Reprod. 1997;12(3):436–440.

    Article  CAS  PubMed  Google Scholar 

  67. Mizutani T, Sugihara A, Honma H, Komura H, Nakamuro K, Terada N. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy. Gynecol Endocrinol. 2005;20(2):80–83.

    Article  CAS  PubMed  Google Scholar 

  68. Dragojevic-Dikic S, Vucic M. The application of GnRH analogues in the treatment of uterine myomas in perimenopausal women. Ginekol Pol. 1998;69(1):28–33.

    CAS  PubMed  Google Scholar 

  69. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 1993;76(5):1217–1223.

    CAS  PubMed  Google Scholar 

  70. Nakayama H, Yano T, Sagara Y, et al. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. Gynecol Endocrinol. 1999;13(6):382–389.

    Article  CAS  PubMed  Google Scholar 

  71. Wang Y, Yano T, Kikuchi A, et al. Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist. J Endocrinol. 2000;165(2):467–473.

    Article  CAS  PubMed  Google Scholar 

  72. Friedman AJ, Daly M, Juneau-Norcross M, et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ‘‘add-back’’ regimens for women with leiomyomata uteri. J Clin Endocrinol Metab. 1993;76(6):1439–1445.

    CAS  PubMed  Google Scholar 

  73. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years. Hum Reprod. 1994;9(9):1618–1625.

    Article  CAS  PubMed  Google Scholar 

  74. Riggs BL. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women. J Clin Endocrinol Metab. 1996;81(7):2417–2418.

    CAS  PubMed  Google Scholar 

  75. Kloosterboer HJ, Ederveen AG. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments. J Steroid Biochem Mol Biol. 2002;83(1–5):157–165.

    Article  CAS  PubMed  Google Scholar 

  76. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. Fertil Steril. 1999;72(5):889–895.

    Article  CAS  PubMed  Google Scholar 

  77. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;(2):CD000547.

  78. Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod. 1999;14(1):44–48.

    Article  CAS  PubMed  Google Scholar 

  79. De Pergola G, Pannacciulli N, Zamboni M, et al. Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women. Diabetes Nutr Metab. 2001;14(5):253–258.

    PubMed  Google Scholar 

  80. Palomba S, Orio F Jr, Russo T, Falbo A, Amati A, Zullo F. Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life. Fertil Steril. 2004;82(2):480–482.

    Article  CAS  PubMed  Google Scholar 

  81. Palomba S, Russo T, Orio F Jr, et al. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Hum Reprod. 2004;19(2):415–421.

    Article  CAS  PubMed  Google Scholar 

  82. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol. 2001;184(3):350–353.

    Article  PubMed  Google Scholar 

  83. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2000;(2):CD000547.

  84. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109(10):1097–1108.

    Article  CAS  PubMed  Google Scholar 

  85. Golan A. GnRH analogues in the treatment of uterine fibroids. Hum Reprod. 1996;11(suppl 3):33–41.

    Article  CAS  PubMed  Google Scholar 

  86. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 1997;12(9):2028–2035.

    Article  CAS  PubMed  Google Scholar 

  87. Campo S, Campo V, Gambadauro P. Short-term and long-term results of resectoscopic myomectomy with and without pretreatment with GnRH analogs in premenopausal women. Acta Obstet Gynecol Scand. 2005;84(8):756–760.

    Article  PubMed  Google Scholar 

  88. ACOG practice bulletin. Surgical alternatives to hysterectomy in the management of leiomyomas. Number 16, May 2000 (replaces educational bulletin number 192, May 1994). Int J Gynaecol Obstet. 2001;73(3):285–293.

    Article  Google Scholar 

  89. Dubuisson JB, Fauconnier A, Fourchotte V, Babaki-Fard K, Coste J, Chapron C. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod. 2001;16(8):1726–1731.

    Article  CAS  PubMed  Google Scholar 

  90. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002;301(1):95–102.

    Article  CAS  PubMed  Google Scholar 

  91. Samant MP, Hong DJ, Croston G, Rivier C, Rivier J. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5. Biopolymers. 2005;80(2–3):386–391.

    Article  CAS  PubMed  Google Scholar 

  92. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–645.

    Article  CAS  PubMed  Google Scholar 

  93. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–551.

    Article  CAS  PubMed  Google Scholar 

  94. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93(1):63–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol. 2009;115(1):132–134.

    Article  PubMed  Google Scholar 

  96. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–537.

    Article  CAS  PubMed  Google Scholar 

  97. Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2007;(4):CD005287.

  98. Zbucka M, Miltyk W, Bielawski T, Surazynski A, Palka J, Wolczynski S. Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells. Folia Histochem Cytobiol. 2007;45(suppl 1):S181–S185.

    PubMed  Google Scholar 

  99. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene. Prescrire Int. 2009;18(104):247.

  100. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res. 1997;48(4):155–163.

    Article  CAS  PubMed  Google Scholar 

  101. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000;295(2):431–437.

    CAS  PubMed  Google Scholar 

  102. Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril. 2001;76(1):38–43.

    Article  CAS  PubMed  Google Scholar 

  103. Palomba S, Orio F Jr, Russo T, et al. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in post-menopausal women. Fertil Steril. 2005;84(1):154–161.

    Article  CAS  PubMed  Google Scholar 

  104. Premkumar A, Venzon DJ, Avila N, et al. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril. 2007;88(6):1637–1644.

    Article  CAS  PubMed  Google Scholar 

  105. Aromatase Inhibitors for Treatment of Uterine Leiomyomas. In: USNIo Health. Clinical Trials Gov 2010.

  106. Todorova VK, Kaufmann Y, Luo S, Suzanne Klimberg V. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol. 2010.

  107. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab. 1993;77(2):324–331.

    CAS  PubMed  Google Scholar 

  108. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431–2442.

    Article  CAS  PubMed  Google Scholar 

  109. Ishikawa H, Reierstad S, Demura M, et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab. 2009;94(5):1752–1756.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22(6):1696–1704.

    Article  CAS  PubMed  Google Scholar 

  111. Bedaiwy MA, Lui J. Long-term management of endometriosis: medical therapy and treatment of infertility. Sex Reprod Menopause. 2010;8(3):5.

  112. Baird DT, Brown A, Cheng L, et al. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids. 2003;68(10–13):1099–1105.

    Article  CAS  PubMed  Google Scholar 

  113. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, Makedos GA, Vlassis GD. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007;110(3):643–649.

    Article  CAS  PubMed  Google Scholar 

  114. Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93(1):192–198.

    Article  CAS  PubMed  Google Scholar 

  115. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433–2442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010;28(3):260–273.

    Article  CAS  PubMed  Google Scholar 

  117. Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab. 2008;93(12):4664–4671.

    Article  CAS  PubMed  Google Scholar 

  118. Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MC, Hernandez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008;112(5):1029–1036.

    Article  PubMed  Google Scholar 

  119. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1381–1387.

    Article  CAS  PubMed  Google Scholar 

  120. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870–1879.

    Article  CAS  PubMed  Google Scholar 

  121. Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004;88(3):277–288.

    Article  CAS  PubMed  Google Scholar 

  122. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008;23(9):2072–2079.

    Article  CAS  PubMed  Google Scholar 

  123. Lalitkumar PG, Lalitkumar S, Meng CX, et al. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod. 2007;22(11):3031–3037.

    Article  CAS  PubMed  Google Scholar 

  124. Sharts-Engel NC. The RU 486 story: the French experience. MCN Am J Matern Child Nurs. 1992;17(1):56.

    Article  CAS  Google Scholar 

  125. Brahma PK, Martel KM, Christman GM. Future directions in myoma research. Obstet Gynecol Clin North Am. 2006;33(1):199–224, xiii.

    Article  PubMed  Google Scholar 

  126. Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol. 2006;4(suppl 1): S8.

  127. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21(4):318–324.

    Article  PubMed  Google Scholar 

  128. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004;103(6):1331–1336.

    Article  CAS  PubMed  Google Scholar 

  129. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007;87(6):1399–1412.

    Article  CAS  PubMed  Google Scholar 

  130. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005;20(4):1090–9.

    Article  CAS  PubMed  Google Scholar 

  131. Boehm KD, Daimon M, Gorodeski IG, Sheean LA, Utian WH, Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev. 1990;27(2):93–101.

    Article  CAS  PubMed  Google Scholar 

  132. Determination of the Lowest, Safe and Effective Dose of the Anti-Progestin, Proellex, in Healthy Women. Clinical Trials, 2010.

  133. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011;95(2):767–772 e1–e2.

    Article  CAS  PubMed  Google Scholar 

  134. Melli MS, Farzadi L, Madarek EO. Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression. Saudi Med J. 2007;28(3):445–450.

    PubMed  Google Scholar 

  135. Fiscella K, Eisinger S. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;112(3):707; author reply 07–8.

    Article  Google Scholar 

  136. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(5):1129–1136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Hoppener JW, Mosselman S, Roholl PJ, et al. Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J. 1988;7(5):1379–1385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Gloudemans T, Prinsen I, Van Unnik JA, Lips CJ, Den Otter W, Sussenbach JS. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res. 1990;50(20):6689–6695.

    CAS  PubMed  Google Scholar 

  139. Norstedt G, Levinovitz A, Eriksson H. Regulation of uterine insulin-like growth factor I mRNA and insulin-like growth factor II mRNA by estrogen in the rat. Acta Endocrinol (Copenh). 1989;120(4):466–472.

    Article  CAS  Google Scholar 

  140. Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol. 1990;76(3 pt 1):388–394.

    CAS  PubMed  Google Scholar 

  141. Cohen O, Schindel B, Homburg R. Uterine leiomyomata–a feature of acromegaly. Hum Reprod. 1998;13(7):1945–1946.

    Article  CAS  PubMed  Google Scholar 

  142. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study. Lancet. 1981;1(8220 pt 1):577–580.

    Article  CAS  PubMed  Google Scholar 

  143. De Leo V, la Marca A, Morgante G, Severi FM, Petraglia F. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Fertil Steril. 2001;75(3):632–633.

    Article  PubMed  Google Scholar 

  144. Feelders RA, Hofland LJ, van Aken MO, et al. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. 2009;69(16):2207–2226.

    Article  CAS  PubMed  Google Scholar 

  145. Davies PH, Stewart SE, Lancranjan I, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly. Clin Endocrinol. 1998;48(3):311–316.

    Article  CAS  Google Scholar 

  146. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. 1994;61(1):70–77.

    Article  CAS  PubMed  Google Scholar 

  147. Sayyah-Melli M, Tehrani-Gadim S, Dastranj-Tabrizi A, et al. Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes. Saudi Med J. 2009;30(8):1024–1033.

    PubMed  Google Scholar 

  148. Steingold KA, Lu JK, Judd HL, Meldrum DR. Danazol inhibits steroidogenesis by the human ovary in vivo. Fertil Steril. 1986;45(5):649–654.

    Article  CAS  PubMed  Google Scholar 

  149. De Leo V, la Marca A, Morgante G. Short-term treatment of uterine fibromyomas with danazol. Gynecol Obstet Invest. 1999;47(4):258–262.

    Article  PubMed  Google Scholar 

  150. La Marca A, Musacchio MC, Morgante G, Petraglia F, De Leo V. Hemodynamic effect of danazol therapy in women with uterine leiomyomata. Fertil Steril. 2003;79(5):1240–1242.

    Article  PubMed  Google Scholar 

  151. Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids. Cochrane Database Syst Rev. 2009;(3):CD007692.

  152. La Marca A, Giulini S, Vito G, Orvieto R, Volpe A, Jasonni VM. Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply. Fertil Steril. 2004;82(6):1694–1696.

    Article  PubMed  Google Scholar 

  153. Coutinho EM. Treatment of large fibroids with high doses of gestrinone. Gynecol Obstet Invest. 1990;30(1):44–47.

    Article  CAS  PubMed  Google Scholar 

  154. Xiao B, Zeng T, Wu S, Sun H, Xiao N. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception. 1995;51(6):359–365.

    Article  CAS  PubMed  Google Scholar 

  155. Harrison-Woolrych M, Raine JM. Levonorgestrel intrauterine device can be left in place for five years. BMJ. 1998;317(7151):149A.

    Article  PubMed Central  Google Scholar 

  156. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991;44(5):473–480.

    Article  CAS  PubMed  Google Scholar 

  157. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception. 1995;52(5):269–276.

    Article  CAS  PubMed  Google Scholar 

  158. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97(8):690–694.

    Article  CAS  PubMed  Google Scholar 

  159. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105(6):592–598.

    Article  CAS  PubMed  Google Scholar 

  160. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception. 1995;51(4):231–235.

    Article  CAS  PubMed  Google Scholar 

  161. Maruo T, Ohara N, Matsuo H, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007;75(6 suppl):S99–S103.

    Article  CAS  PubMed  Google Scholar 

  162. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ. 1998;316(7138):1122–1126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95(1):247–253.

    Article  CAS  PubMed  Google Scholar 

  164. Halder SK, Sharan C, Al-Hendy A. Vitamin D treatment induces dramatic shrinkage of uterine leiomyomas growth in the Eker rat model. Fertil Steril. 2010;94(4):S75–S76.

    Article  Google Scholar 

  165. Halder SK, Goodwin S, Al-Hendy A. Vitamin D exhibits anties-trogenic effects in human uterine leiomyoma cells. Fertil Steril. 2010;94(4):S219–S220.

    Article  Google Scholar 

  166. Halder SK, Sharan C, Goodwin S, Al-Hendy A. 1, 25 dihydroxyvitamin D3 disorganizes actin fibers in human immortalized uterine leiomyoma cells. Fertil Steril. 2009;92(3):S127–S128.

    Article  Google Scholar 

  167. Abdelraheem MS, Al-Hendy A. Serum vitamin D3 level inversely correlates with total fibroid tumor burden in women with symptomatic uterine fibroid. Fertil Steril. 2010;94(4):S74.

    Article  Google Scholar 

  168. Lin JK, Liang YC, Lin-Shiau SY. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol. 1999;58(6):911–915.

    Article  CAS  PubMed  Google Scholar 

  169. Joo Eun C, Motoichi K, Young-Jin K, Hiroshi U, Shiro K. Amplification of antioxidant activity of catechin by polycondensation with acetaldehyde. Biomacromolecules. 2004;5(1):113–118.

    Article  CAS  Google Scholar 

  170. Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. Toxicol Sci. 1999;52(2 suppl):111–117.

    Article  CAS  PubMed  Google Scholar 

  171. Ahmad N, Cheng P, Mukhtar H. Cell Cycle Dysregulation by Green Tea Polyphenol Epigallocatechin-3-Gallate. Biochem Biophys Res Commun. 2000;275(2):328–334.

    Article  CAS  PubMed  Google Scholar 

  172. Chen C, Yu R, Owuor ED, Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res. 2000;23(6):605–612.

    Article  CAS  PubMed  Google Scholar 

  173. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth Inhibition, Cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol. 2000;164(1):82–90.

    Article  CAS  PubMed  Google Scholar 

  174. Tang Y, Zhao DY, Elliott S, et al. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol. 2007;31(4):705–711.

    CAS  PubMed  Google Scholar 

  175. Dong Z, Mohamed AH, Gloria RD, Valerie MR, Veera R, Ayman AH. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010;94(5):1887–1893.

    Article  CAS  Google Scholar 

  176. Zhang D, Al-Hendy M, Richard-Davis G, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in vivo. Am J Obstet Gynecol. 2010;202(3):289e1–289e9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ayman Al-Hendy MD, PhD, FRCSC, FACOG.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sabry, M., Al-Hendy, A. Medical Treatment of Uterine Leiomyoma. Reprod. Sci. 19, 339–353 (2012). https://doi.org/10.1177/1933719111432867

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719111432867

Keywords

Navigation